Literature DB >> 4064996

Incidence and risk factors for symptomatic patent ductus arteriosus among inborn very-low-birth-weight infants.

J A Furzan, J Reisch, J E Tyson, P Laird, C R Rosenfeld.   

Abstract

The incidence of symptomatic patent ductus arteriosus (sPDA) in very-low-birth-weight infants has been reported almost exclusively from referral centers. Moreover, the incidence has varied considerably. We prospectively evaluated the incidence and risk factors of sPDA in a totally inborn population of infants less than or equal to 1500 g birth weight (n = 120) receiving conservative fluid management and examined the role of echocardiography in predicting sPDA before clinical signs are evident. The incidence of sPDA was relatively low (16%) and the age at onset was relatively late (mean +/- S.E. = 14.7 +/- 3.0 days) when compared to prior reports. Echocardiographic changes preceded physical and radiographic findings of sPDA. Fluid volume within the range administered to our infants was unrelated to the occurrence of sPDA. However, risk factors identifiable within 24 h of birth were defined: obstetric estimate of gestational age, race, mean fluid volume intake in the initial 24 h, and early treatment with volume expanders. From these risk factors, 79% of infants with sPDA and 79% without sPDA could be predicted by stepwise discriminant function analyses. These findings may be employed in studies needed to assess the benefit of early surgical or pharmacologic therapy for infants at highest risk for sPDA.

Entities:  

Mesh:

Year:  1985        PMID: 4064996     DOI: 10.1016/0378-3782(85)90135-5

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  9 in total

1.  Functional Neonatal Echocardiography: Indian Experience.

Authors:  Anilkumar Mohan Khamkar; Pradeep B Suryawanshi; Rajesh Maheshwari; Suprabha Patnaik; Nandini Malshe; Vijay Kalrao; Sanjay Lalwani; Jitendra Surwade
Journal:  J Clin Diagn Res       Date:  2015-12-01

2.  Conservative treatment for patent ductus arteriosus in the preterm.

Authors:  Sophie Vanhaesebrouck; Inge Zonnenberg; Piet Vandervoort; Els Bruneel; Marie-Rose Van Hoestenberghe; Claire Theyskens
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-01-09       Impact factor: 5.747

Review 3.  Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?

Authors:  Ronald I Clyman; James Couto; Gail M Murphy
Journal:  Semin Perinatol       Date:  2012-04       Impact factor: 3.300

4.  Variation in the diagnosis and management of patent ductus arteriosus in premature infants.

Authors:  L S Lai; B W McCrindle
Journal:  Paediatr Child Health       Date:  1998-11       Impact factor: 2.253

Review 5.  Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period.

Authors:  Jeff Reese; Alex Veldman; Lisa Shah; Megan Vucovich; Robert B Cotton
Journal:  Semin Perinatol       Date:  2010-06       Impact factor: 3.300

6.  Effects of Advancing Gestation and Non-Caucasian Race on Ductus Arteriosus Gene Expression.

Authors:  Nahid Waleh; Anne Marie Barrette; John M Dagle; Allison Momany; Chengshi Jin; Nancy K Hills; Elaine L Shelton; Jeff Reese; Ronald I Clyman
Journal:  J Pediatr       Date:  2015-08-08       Impact factor: 4.406

7.  Patent ductus arteriosus in premature neonates.

Authors:  Olachi J Mezu-Ndubuisi; Ghanshyam Agarwal; Aarti Raghavan; Jennifer T Pham; Kirsten H Ohler; Akhil Maheshwari
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

Review 8.  Sex Differences in Patent Ductus Arteriosus Incidence and Response to Pharmacological Treatment in Preterm Infants: A Systematic Review, Meta-Analysis and Meta-Regression.

Authors:  Moreyba Borges-Lujan; Gema E Gonzalez-Luis; Tom Roosen; Maurice J Huizing; Eduardo Villamor
Journal:  J Pers Med       Date:  2022-07-14

Review 9.  Application of NPE in the assessment of a patent ductus arteriosus.

Authors:  David van Laere; Bart van Overmeire; Samir Gupta; Afif El-Khuffash; Marilena Savoia; Patrick J McNamara; Christoph E Schwarz; Willem P de Boode
Journal:  Pediatr Res       Date:  2018-07       Impact factor: 3.756

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.